Trial · NCT07162649
Dexmedetomidine Nasal Spray for the Treatment of Panic Attacks in Adults
NCT07162649, Not applicable, Completed, Tongji University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Dexmedetomidine Nasal Spray for the Treatment of Panic Attacks in Adults. Trials, record NCT07162649. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07162649
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Dexmedetomidine Nasal Spray for the Treatment of Panic Attacks in Adults
- NCT number
- NCT07162649
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 40 participants, actual
- Lead sponsor
- Tongji University
- Conditions
- Dexmedetomidine, Panic Attacks
- Interventions
- Dexmedetomidine, Placebo
- First posted
- 2025-09-09
- Last updated
- 2026-10-16
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 30-minute response rate using Clinical Global Impression-Efficacy Index (CGI-EI) | 30 minutes post-administration | Proportion of participants achieving a CGI-Efficacy Index \>1.0 at 30 minutes post-dose, indicating clinically significant symptom improvement. CGI-EI is a validated clinician-rated scale assessing therapeutic effect relative to side effects. |
| Secondary | Change in core panic symptom count | Baseline and 30 minutes post-administration | Reduction in the number of DSM-5-defined core panic symptoms (e.g., palpitations, trembling, choking sensations) self-reported by participants at 30 minutes post-dose. |
| Secondary | Change in Visual Analogue Scale for Anxiety (VAS-A) score | Baseline and 30 minutes post-administration | Reduction in self-reported anxiety severity measured on a 0-10 VAS-A scale (0=no anxiety; 10=maximum anxiety) at 30 minutes post-dose. |
| Other | Incidence of Treatment-Emergent Adverse Events (TEAEs) | within 2 weeks post-dose | Frequency of adverse events (e.g., bradycardia, hypotension, nasal irritation, somnolence), serious adverse events (SAEs), abnormal vital signs (BP, HR, RR, SpO₂), and clinically significant ECG changes within 2 weeks post-dose. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07162649
GET https://conductscience.org/api/trials/v1/NCT07162649/registered